Clinical trials: Covid
Coronavirus
Behavior, Environment And Treatments for Covid-19
Background: During the current COVID-19 pandemic there is urgent need for information about the natural history of the infection in non-hospitalized patients, including the severity and duration of symptoms, and outcome from…
- Trial name
- BEAT19 (NCT04321811)
- Testing
- Observation of patients with known, suspected, or at risk for COVID-19 infection
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- xCures
COVID-19
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
The study is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of tofacitinib in hospitalized adult participants with COVID-19 pneumonia who are receiving SoC…
- Trial name
- NCT04412252
- Testing
- Tofacitinib
- Where
- 6 sites in United States
- Sponsor
- Pfizer
Fatigue, Dyspnea
TaiChi-DTx for Treating Long Covid Symptoms
The randomized controlled trial will be conducted to evaluate the effectiveness of a Multi-domain Tai Chi Digital Therapy for treating the individuals suffering from the long term COVID-19 syndrome (Long COVID).
- Conditions
- Fatigue, Dyspnea, Cognitive Impairment, Muscle Pain
- Trial name
- TaiChi-DTx (NCT05419219)
- Testing
- the multi-domain Tai Chi Digital therapy Software Application
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tim Shi
Post COVID-19 Condition
Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)
After an acute episode of COVID-19, many patients experience persistent or recurrent symptoms with substantial impairment of their quality of life.
- Trial name
- ECHAP-COVID (NCT05532904)
- Testing
- Personalized multidisciplinary day-hospital intervention
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Long COVID
Cognitive Rehabilitation for Long COVID
The investigators are comparing two different methods for helping adults with Long Coronavirus (COVID) also known as Post-Coronavirus Syndrome or Post-Coronavirus Condition manage everyday cognitive challenges.
- Trial name
- STAR-C3 (NCT05676047)
- Testing
- Cognitive Rehabilitation, Education
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- McMaster University
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
Coronavirus-induced disease 2019 (COVID-19) is an infection caused by a virus whose full name is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- INHERIT (NCT05204550)
- Testing
- unfractionated heparin, 0.9%sodium chloride
- Where
- Australia
- Volunteers
- 506 people
- Sponsor
- Murdoch Childrens Research Institute
COVID-19, Corona Virus Infection
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
This a double-blind, randomized, placebo-controlled clinical trial to determine if primary prophylaxis with hydroxychloroquine in healthcare workers reduces symptomatic COVID-19 infection.
- Conditions
- COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis
- Trial name
- HCQPreP (NCT04363450)
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to <55 and 65 to <85 years of age，with the randomized, observer-blind…
- Trial name
- NCT04398147
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- Canada
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
2019-nCoV
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment…
- Trial name
- NCT04255017
- Testing
- Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
COVID 19
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
Nasal saline irrigations are a safe and commonly used mechanism to treat a variety of sinonasal diseases including sinusitis, rhinitis, and upper respiratory tract infections.
- Trial name
- NCT04347538
- Testing
- Saline Nasal Irrigation
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Vanderbilt University Medical Center
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
SARS-CoV-2 Donor-Recipient Immunity Transfer
This study investigates whether donors with previous exposure to COVID-19 can pass their immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have not been exposed.
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04666025
- Testing
- Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
SARS-CoV2, COVID-19
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended…
- Trial name
- NCT06672055
- Testing
- VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
- Where
- 145 sites in United States
- Volunteers
- 5,485 people
- Sponsor
- Vaxart
SARS-CoV-2, Safety
The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
This study plans to enrol 1000 participants 18 years and above, with ≥10% participants ≥60 years old. According to SARS-CoV-2 vaccine vaccination history, they will be evenly divided into 2 groups, Group A and Group B.
- Conditions
- SARS-CoV-2, Safety, Immunotoxicity
- Trial name
- NCT05492643
- Testing
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity, Humoral Immunity
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
SARS-CoV-2
Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients
To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately symptomatic COVID19.
- Trial name
- COVIDEYE (NCT04654325)
- Testing
- conjunctival swab
- Where
- France
- Volunteers
- 534 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID, SARS-CoV2
Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR
The current coronavirus disease pandemic has posed a problem and a challenge for health systems globally. In the framework of a pandemic, a diagnosis is a key tool in containing and monitoring disease outbreaks.
- Conditions
- COVID, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04468217
- Testing
- Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples
- Where
- Chile
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Neurognos
Pneumococcal Infection
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease…
- Trial name
- NCT05158140
- Testing
- V110, V114, mRNA-1273
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neuromuscular Blockade, Human Characteristics
Sparing in Neuromuscular Blockade in COVID 19 ICU
This is a retrospective case-controlled study of the effect of the use of a neuromuscular blockade (NMB) monitor on the consumption of NMB agents in patients under mechanical ventilation in the context of COVID-19.
- Conditions
- Neuromuscular Blockade, Human Characteristics, Complication of Medical Care, Intensive Care Unit Acquired Weakness
- Trial name
- TOF-COVID (NCT04459533)
- Testing
- TOF protocol
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Hospices Civils de Lyon
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.